[Current use of prostaglandins E2].
Prostaglandins E2 have been used since 1959 and introduced in France since 1966. Their main indication is to pre-induce labor in order to mature a cervix barely open (below 6) and induce labor. For the pre-inducement, the extra-amniotic route seems most interesting in a gel form at a dose of 0.500 microgram (Gelovect): the gain on the cervical opening is 1 to 2 points and labor is induced in 50 to 60 p. cent of the cases, without any other treatment, by artificial rupture of the membranes. For inducing labor, the venous route may be interesting when the condition of the cervix is less than optimum, especially in premature rupture of the membranes. The effectiveness is comparable to that of pitocin, but 10 times more potent resulting in a much more strict control of its prescription by intravenous route. The doses used are 0.15 to 0.25 microgram per minute to a maximum of 2 micrograms per minute. Intravenous prostaglandins E2 should not be used concomitantly with pitocin. Other local administration routes are less used in France. In the immediate post-partum, prostaglandins E2 are interesting parenterally (2 to 4 micrograms per minute) or in the myometrium in case of severe haemorrhages. In 2nd trimester miscarriages, maturation of the cervix may be used but prostaglandin-like substances, either PGE (Geneprost) or prostaglandins E2-like products are preferred, intramuscularly.
D000028:Abortion, Induced; D000650:Amnion; D015232:Dinoprostone; D005260:Female; D006801:Humans; D007267:Injections; D007275:Injections, Intravenous; D007751:Labor, Induced; D011247:Pregnancy; D011458:Prostaglandins E / Q000008:administration & dosage* / Q000009:adverse effects
D011458:Prostaglandins E; D015232:Dinoprostone
Utilisation actuelle des prostaglandines E2.